Payment overview · 2025
General Payments
$17,082.34
67 reported records · 15 companies
Healthcare provider profile · identity verified
Weining W Liang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLUSHING, NY · NPI 1033222831
Verified facts
What the public records show
CMS Open Payments records show Weining W Liang, MD received $17,082.34 in general payments during 2025 across 67 reported records.
ABBVIE INC. accounted for 58.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Ibsrela, Licart, Linzess, Ozempic, Rybelsus, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 595 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 392 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Zenpep by this doctor in 2024.
Ardelyx, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBSRELA as an associated drug or biological on 59980 records involving 18215 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Ibsrela by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Shingrix by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Licart as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Licart by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $10,009.50 | 58.6% | 24 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $6,539.69 | 38.3% | 18 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $106.79 | 0.6% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $79.68 | 0.5% | 4 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $54.64 | 0.3% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $46.64 | 0.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.43 | 0.3% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.51 | 0.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.44 | 0.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.91 | 0.1% | 2 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $24.05 | 0.1% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $23.99 | 0.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.76 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.09 | 0.1% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.22 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,525.00 | 8 |
| Food and Beverage | $1,557.34 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CREON Normalized: creon |
Drug | ABBVIE INC. | $7,980.49 | 15 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $132.27 | 6 | 2025 |
Source payment records
|
|||||
| OPZELURA Normalized: opzelura |
Drug | Incyte Corporation | $106.79 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $79.68 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $57.13 | 3 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $54.64 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $46.64 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $46.43 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.51 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.91 | 2 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.74 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.09 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 595 | exact normalized | Medicare Part D |
| IBSRELA ibsrela |
2025 | Ibsrela | 2024 | 35 | exact normalized | Medicare Part D |
| Licart licart |
2025 | Licart | 2024 | 89 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 392 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 83 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 81 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
595 | 123 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
392 | 86 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Ardelyx, Inc. Exact reporting entity; no affiliate inference |
2025 | IBSRELA open payments reported associated product |
CMS Open Payments — General Payments 59980 supporting records · 18215 recipient NPIs · example record 1247828901 |
Ibsrela · 2024 Exact normalized brand match · 1 Part D row |
35 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
110 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
54 | 47 |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Licart open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Licart · 2024 Exact normalized brand match · 1 Part D row |
89 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
178 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
83 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
81 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
119 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Vascepa | Icosapent Ethyl | 2024 | 281 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1380 | 215 |
| Losartan Potassium | Losartan Potassium | 1111 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 1103 | 166 |
| Simvastatin | Simvastatin | 1083 | 157 |
| Metformin Hcl | Metformin Hcl | 990 | 145 |
| Diclofenac Epolamine | Diclofenac Epolamine | 932 | 167 |
| Alendronate Sodium | Alendronate Sodium | 849 | 116 |
| Tamsulosin Hcl | Tamsulosin Hcl | 787 | 120 |
| Omeprazole | Omeprazole | 733 | 173 |
| Celecoxib | Celecoxib | 721 | 135 |
| Creon | Lipase/Protease/Amylase | 595 | 123 |
| Diclofenac Sodium | Diclofenac Sodium | 552 | 125 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 492 | 127 |
| Montelukast Sodium | Montelukast Sodium | 475 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 427 | 65 |
| Ammonium Lactate | Ammonium Lactate | 415 | 95 |
| Donepezil Hcl | Donepezil Hcl | 408 | 62 |
| Gemfibrozil | Gemfibrozil | 406 | 58 |
| Linzess | Linaclotide | 392 | 86 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 386 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 384 | 75 |
| Clobetasol Propionate | Clobetasol Propionate | 383 | 86 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 380 | 81 |
| Fluticasone Propionate | Fluticasone Propionate | 352 | 90 |
| Finasteride | Finasteride | 349 | 62 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 348 | 78 |
| Famotidine | Famotidine | 346 | 66 |
| Ketoconazole | Ketoconazole | 324 | 74 |
| Azithromycin | Azithromycin | 323 | 214 |
| Meclizine Hcl | Meclizine Hcl | 320 | 86 |
| Azelastine Hcl | Azelastine Hcl | 305 | 64 |
| Allopurinol | Allopurinol | 302 | 50 |
| Mometasone Furoate | Mometasone Furoate | 302 | 62 |
| Levothyroxine Sodium | Levothyroxine Sodium | 297 | 33 |
| Lisinopril | Lisinopril | 294 | 52 |
| Valsartan | Valsartan | 275 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 273 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 46 |
| Icosapent Ethyl | Icosapent Ethyl | 263 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 262 | 77 |
| Glipizide Er | Glipizide | 245 | 38 |
| Restasis | Cyclosporine | 244 | 46 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 243 | 165 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 229 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 225 | 33 |
| Atenolol | Atenolol | 224 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 223 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 33 |
| Tacrolimus | Tacrolimus | 211 | 34 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 210 | 47 |
| Halobetasol Propionate | Halobetasol Propionate | 209 | 46 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 207 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 201 | 37 |
| Bepotastine Besilate | Bepotastine Besilate | 199 | 46 |
| Januvia | Sitagliptin Phosphate | 198 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 194 | 146 |
| Colchicine | Colchicine | 194 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 182 | 35 |
| Metformin Hcl Er | Metformin Hcl | 182 | 31 |
| Jardiance | Empagliflozin | 178 | 33 |
| Fluocinonide | Fluocinonide | 174 | 57 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 169 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 165 | 50 |
| Lactulose | Lactulose | 164 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 161 | 22 |
| Folic Acid | Folic Acid | 147 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 147 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 144 | 19 |
| Trazodone Hcl | Trazodone Hcl | 138 | 39 |
| Clemastine Fumarate | Clemastine Fumarate | 132 | 32 |
| Dexlansoprazole Dr | Dexlansoprazole | 129 | 28 |
| Lansoprazole | Lansoprazole | 128 | 29 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 121 | 24 |
| Eliquis | Apixaban | 119 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 119 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 110 | 85 |
| Vemlidy | Tenofovir Alafenamide | 110 | 14 |
| Hydrocortisone | Hydrocortisone | 107 | 35 |
| Loperamide | Loperamide Hcl | 107 | 59 |
| Memantine Hcl Er | Memantine Hcl | 105 | 18 |
| Farxiga | Dapagliflozin Propanediol | 104 | 18 |
| Nitroglycerin | Nitroglycerin | 102 | 45 |
| Clonidine Hcl | Clonidine Hcl | 101 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 14 |
| Mupirocin | Mupirocin Calcium | 96 | 24 |
| Lidocaine | Lidocaine | 94 | 27 |
| Xarelto | Rivaroxaban | 93 | 16 |
| Erythromycin | Erythromycin Base | 91 | 25 |
| Ibuprofen | Ibuprofen | 90 | 55 |
| Meloxicam | Meloxicam | 90 | 29 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 89 | 12 |
| Licart | Diclofenac Epolamine | 89 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 88 | 11 |
| Mesalamine | Mesalamine | 85 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 20 |
| Ozempic | Semaglutide | 83 | 27 |
| Glimepiride | Glimepiride | 81 | 12 |
| Rybelsus | Semaglutide | 81 | 20 |
| Sertraline Hcl | Sertraline Hcl | 77 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 75 | 20 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 75 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 74 | 22 |
| Nifedipine Er | Nifedipine | 74 | 11 |
| Verapamil Er | Verapamil Hcl | 74 | 12 |
| Ciclopirox | Ciclopirox Olamine | 73 | 15 |
| Glipizide | Glipizide | 72 | 16 |
| Dutasteride | Dutasteride | 69 | suppressed |
| Carvedilol | Carvedilol | 67 | suppressed |
| Clotrimazole | Clotrimazole | 65 | 20 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 65 | 32 |
| Acyclovir | Acyclovir | 64 | 22 |
| Amoxicillin | Amoxicillin | 63 | 50 |
| Prednisone | Prednisone | 63 | 36 |
| Alcohol Pads | Alcohol Antiseptic Pads | 61 | 19 |
| Fenofibrate | Fenofibrate | 61 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 58 | 12 |
| Tradjenta | Linagliptin | 58 | suppressed |
| Mupirocin | Mupirocin | 56 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 54 | 15 |
| Gabapentin | Gabapentin | 54 | 14 |
| Ranolazine Er | Ranolazine | 54 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 54 | 47 |
| Lubiprostone | Lubiprostone | 53 | 11 |
| Cyclosporine | Cyclosporine | 52 | 26 |
| Metformin Er Gastric | Metformin Hcl | 52 | suppressed |
| Diflorasone Diacetate | Diflorasone Diacetate | 51 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 50 | suppressed |
| Verapamil Sr | Verapamil Hcl | 50 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 49 | suppressed |
| Furosemide | Furosemide | 49 | 12 |
| Procto-Med Hc | Hydrocortisone | 49 | suppressed |
| Rivastigmine | Rivastigmine | 49 | suppressed |
| Trulicity | Dulaglutide | 48 | 16 |
| Enalapril Maleate | Enalapril Maleate | 47 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 47 | suppressed |
| Minoxidil | Minoxidil | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | 32 |
| Clarithromycin | Clarithromycin | 46 | 40 |
| Naproxen | Naproxen | 46 | 15 |
| Baclofen | Baclofen | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | suppressed |
| Ciclopirox | Ciclopirox | 42 | 16 |
| Diclofenac Potassium | Diclofenac Potassium | 42 | 16 |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 42 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 36 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 39 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Entecavir | Entecavir | 38 | suppressed |
| Telmisartan | Telmisartan | 38 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Ibsrela | Tenapanor Hcl | 35 | 19 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 35 | 12 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 33 | suppressed |
| Zileuton Er | Zileuton | 33 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Ursodiol | Ursodiol | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Fluconazole | Fluconazole | 30 | 25 |
| Methocarbamol | Methocarbamol | 30 | 12 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 29 | 25 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 29 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Rapaflo | Silodosin | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Tavaborole | Tavaborole | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Prolia | Denosumab | 24 | 18 |
| Nexium | Esomeprazole Magnesium | 23 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 23 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 22 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 20 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Dexilant | Dexlansoprazole | 21 | suppressed |
| Nateglinide | Nateglinide | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Olopatadine Hcl | Olopatadine Hcl | 21 | suppressed |
| Varivax Vaccine | Varicella Vaccine Live/Pf | 21 | 21 |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Proctozone-Hc | Hydrocortisone | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Acarbose | Acarbose | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 15 |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 17 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 17 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | 14 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 16 | suppressed |
| Desoximetasone | Desoximetasone | 16 | suppressed |
| Leflunomide | Leflunomide | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Ofloxacin | Ofloxacin | 16 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 16 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 16 | suppressed |
| Procrit | Epoetin Alfa | 16 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 15 | 15 |
| Anastrozole | Anastrozole | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 15 | suppressed |
| Invokana | Canagliflozin | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 15 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Xiidra | Lifitegrast | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Flomax | Tamsulosin Hcl | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Cozaar | Losartan Potassium | 11 | suppressed |
| Desloratadine | Desloratadine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Edarbi | Azilsartan Medoxomil | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $17,082.34 · 67 records | ABBVIE INC. | AIRSUPRA, Arikayce, COMIRNATY, CREON, Flector, IBSRELA, LINZESS, Licart, MOUNJARO, OPZELURA, Ozempic, PREVNAR 20, QULIPTA, REZDIFFRA, Rybelsus, TRELEGY ELLIPTA, Tirosint, UBRELVY, VOQUEZNA, VYALEV, ZENPEP, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error